Holen Sie sich die Stockscreener-App
0.5553
9.70%
-0.0662
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
Seattle InnoDiagrid emerges from stealth I Atossa troubles - The Business Journals
Atossa Genetics Inc. (NASDAQ:ATOS) Sees Large Increase in Short Interest - Defense World
Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200 Day Moving Average – Should You Sell? - Defense World
Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200 Day Moving AverageShould You Sell? - MarketBeat
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Norwich Bulletin
Atossa Genetics (NASDAQ:ATOS) & IDEXX Laboratories (NASDAQ:IDXX) Head-To-Head Survey - Defense World
What margin trends mean for Atossa Therapeutics Inc. stockWeekly Trade Summary & Growth Focused Stock Reports - Улправда
Will Atossa Therapeutics Inc. stock outperform international peersChart Signals & Community Consensus Trade Alerts - Улправда
Earnings Report: Is Atossa Therapeutics Inc. stock a buy before product launchesTake Profit & Smart Money Movement Tracker - Улправда
Atossa Therapeutics Earnings Notes - Trefis
Will Atossa Therapeutics Inc. stock benefit from AI adoptionWeekly Profit Recap & Consistent Return Strategy Ideas - DonanımHaber
Will Atossa Therapeutics Inc. stock maintain growth storyBond Market & Free AI Powered Buy and Sell Recommendations - DonanımHaber
Will Atossa Therapeutics Inc. stock maintain momentum in 2025Quarterly Earnings Report & Technical Pattern Based Signals - Улправда
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category - BioSpace
Atossa Therapeutics Wins R&D Excellence Award for Precision Endocrine Therapy Innovation - Clinical Trials Arena
Atossa Genetics (NASDAQ:ATOS) Stock Crosses Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Atossa Genetics (NASDAQ:ATOS) Stock Crosses Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Atossa Therapeutics (ATOS) Highlights Promising (Z)-endoxifen Tr - GuruFocus
Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium - WV News
Atossa Therapeutics Stock Jumps After FDA Grants Rare Pediatric Status To DMD Drug — Retail Bets On Phase 3 Fast-Track - Stocktwits
Trade Recap: Will Atossa Therapeutics Inc stock gain from lower inflationJuly 2025 Chart Watch & Weekly Chart Analysis and Guides - moha.gov.vn
Atossa gains on rare pediatric disease status for Duchenne asset - MSN
Atossa Therapeutics, Inc. (ATOS) -6.4% in After-hours: Shares Slip Amid Routine Trading - Stocks Telegraph
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy - BioSpace
Volume Recap: Will Atossa Therapeutics Inc stock return to pre crisis levelsMarket Trend Review & Target Return Focused Picks - moha.gov.vn
Atossa Therapeutics (ATOS) Stock: Soars 8% as FDA Grants Rare Pediatric Disease Designation for (Z)-Endoxifen (ATOS) - parameter.io
Why Are Shares Of Atossa Therapeutics Up Today? - Benzinga
Atossa Therapeutics (ATOS) Surges on FDA Pediatric Designation - GuruFocus
Atossa gains on Rare Pediatric Disease status for Duchenne asset - Seeking Alpha
Atossa Therapeutics stock soars after FDA grants rare pediatric disease status - Investing.com UK
Atossa Therapeutics stock soars after FDA grants rare pediatric disease status By Investing.com - Investing.com Nigeria
Atossa Therapeutics (ATOS) Gains FDA Recognition for Duchenne Mu - GuruFocus
Adversity is less terrifying than hope: Atossa Therapeutics Inc (ATOS) - setenews.com
Atossa Therapeutics Announces Issuance of U.S. Patent Covering E - GuruFocus
ATOS Receives New Patent for Endoxifen Formulations - GuruFocus
Atossa Therapeutics receives US patent for endoxifen formulations - Investing.com
Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen - Morningstar
Ascendiant Capital raises Atossa Genetics stock price target to $8 from $7.75 - Investing.com Canada
Ascendiant Capital Markets Forecasts Strong Price Appreciation for Atossa Genetics (NASDAQ:ATOS) Stock - MarketBeat
Ascendiant Capital Maintains Atossa Therapeutics (ATOS) Buy Recommendation - Nasdaq
Ascendiant Capital Raises Price Target for Atossa Therapeutics (ATOS) | ATOS Stock News - GuruFocus
CapEx per share of Atossa Therapeutics, Inc. – BER:YAG2 - TradingView
Analysts Set Atossa Genetics Inc. (NASDAQ:ATOS) Price Target at $6.25 - Defense World
Contrasting Vaso (OTCMKTS:VASO) and Atossa Genetics (NASDAQ:ATOS) - Defense World
Atossa Genetics stock holds Buy rating at H.C. Wainwright on FDA feedback By Investing.com - Investing.com South Africa
Atossa Genetics stock holds Buy rating at H.C. Wainwright on FDA feedback - Investing.com Canada
0.37%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):